Humacyte Income Before Tax vs Operating Income Analysis
| HUMAW Stock | USD 1.47 0.03 2.00% |
Humacyte financial indicator trend analysis is much more than just examining Humacyte latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Humacyte is a good investment. Please check the relationship between Humacyte Income Before Tax and its Operating Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.
Income Before Tax vs Operating Income
Income Before Tax vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Humacyte Income Before Tax account and Operating Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Humacyte's Income Before Tax and Operating Income is 0.54. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Operating Income in the same time period over historical financial statements of Humacyte, assuming nothing else is changed. The correlation between historical values of Humacyte's Income Before Tax and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Humacyte are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Income Before Tax i.e., Humacyte's Income Before Tax and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.54 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Humacyte income statement and is an important metric when analyzing Humacyte profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Operating Income
Operating Income is the amount of profit realized from Humacyte operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Humacyte is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Humacyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.Enterprise Value is likely to climb to about 284.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 6.2M | 1.1M | 1.1M | Depreciation And Amortization | 8.3M | 8.3M | 7.7M | 8.7M |
Humacyte fundamental ratios Correlations
Click cells to compare fundamentals
Humacyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.